Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Common Equity (2020 - 2025)

PROCEPT BioRobotics has reported Common Equity over the past 6 years, most recently at $365.9 million for Q4 2025.

  • Quarterly results put Common Equity at $365.9 million for Q4 2025, down 9.04% from a year ago — trailing twelve months through Dec 2025 was $365.9 million (down 9.04% YoY), and the annual figure for FY2025 was $365.9 million, down 9.04%.
  • Common Equity for Q4 2025 was $365.9 million at PROCEPT BioRobotics, down from $380.3 million in the prior quarter.
  • Over the last five years, Common Equity for PRCT hit a ceiling of $402.2 million in Q4 2024 and a floor of -$206.3 million in Q2 2021.
  • Median Common Equity over the past 5 years was $258.4 million (2022), compared with a mean of $232.5 million.
  • Biggest five-year swings in Common Equity: surged 268.21% in 2021 and later plummeted 34.82% in 2023.
  • PROCEPT BioRobotics' Common Equity stood at $267.1 million in 2021, then fell by 26.22% to $197.1 million in 2022, then surged by 42.46% to $280.8 million in 2023, then soared by 43.27% to $402.2 million in 2024, then decreased by 9.04% to $365.9 million in 2025.
  • The last three reported values for Common Equity were $365.9 million (Q4 2025), $380.3 million (Q3 2025), and $385.8 million (Q2 2025) per Business Quant data.